玻璃体腔注射康柏西普对特发性脉络膜新生血管患者黄斑区形态和功能的影响-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

玻璃体腔注射康柏西普对特发性脉络膜新生血管患者黄斑区形态和功能的影响

The clinical observation of intravitreal conbercept for idiopathic choroidal neovascularization

ES评分 0 浏览量：54 下载量：0

DOI	10.12208/j.ijcr.20250123
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2025, 9(3)
作者	李天贺¹,翟改霞²,宋文琦²,王少鹏²*,
作者单位	1 滨州医学院第一临床医学院山东滨州,2 淄博市中心医院山东淄博
摘要	目的玻璃体腔注射康柏西普对特发性脉络膜新生血管（idiopathic choroidal neovascularization，ICNV）患者黄斑区形态和功能的影响。方法采用回顾性自身对照研究，选取2023年8月至2024年4月在淄博市中心医院眼科诊断为特发性脉络膜新生血管并且进行康柏西普治疗的30例患者（30眼），采用1+按需治疗（pro-re-nata，PRN）治疗方案，且均完成6个月的随访。所有患者均完善了光学相干断层扫描、光学相干断层扫描血流成像、多焦视网膜电图检查。对治疗前、后的最佳矫正视力（best-corrected vision acuity，BCVA）、黄斑中心视网膜厚度（central retinal thickness，CRT）、脉络膜新生血管（choroidal neovascularization，CNV）血流面积、环1P1波振幅密度进行统计学分析。结果治疗前及治疗后6mo BCVA （LogMAR）分别为0.47±0.12及0.26±0.07，治疗后最佳矫正视力与治疗前比较差异有统计学意义（P＜0.05），治疗前CRT为（347.3±58.74）μm，治疗后6mo CRT为（258.6±26.38）μm，与治疗前比较差异有统计学意义（P＜0.05），治疗前CNV血流面积为（0.23±0.05）mm2，治疗后6mo CNV血流面积为（0.11±0.09）mm2，与治疗前相比差异有统计学意义（P＜0.05），治疗前环1P1波振幅密度为（60.90±11.62）nv/deg2，治疗后6mo环1P1波振幅密度为（89.43±11.13）nv/deg2，与治疗前相比差异有统计学意义（P＜0.05）。30只眼均未出现眼内炎、白内障、青光眼、视网膜脱离等严重眼部并发症及心脑血管意外。结论玻璃体腔注射康柏西普对ICNV患者黄斑区的形态和功能均有改善。
Abstract	Objective Effect of intravitreal injection of conbercept on the morphology and function of macular region in patients with idiopathic choroidal neovascularization (ICNV). Methods A retrospective self-control study was conducted. Thirty patients (30 eyes) diagnosed as idiopathic choroidal neovascularization in Zibo Central Hospital from August 2023 to April 2024 were treated with conbercept. They were treated with 1+ pro-re-nata (PRN), and all of them were followed up for 6 months. All patients have improved optical coherence tomography, optical coherence tomography angiography and multifocal electroretinogram. The best-corrected vision acuity (BCVA), central retinal thickness (CRT), blood flow area of choroidal neovascularization (CNV) and amplitude density of P1 wave in ring 1 were statistically analyzed before and after treatment. Results The BCVA (LogMAR)were 0.47±0.12 and 0.26 ±0.07, respectively, before treatment and 6 months after treatment. The best corrected visual acuity after treatment was significantly different from that before treatment (P < 0.05). The CRT before treatment was (347.3±58.74)μm, and the CRT after treatment was (258.6±26.38)μm. Compared with before treatment, the difference was statistically significant (P < 0.05). The blood flow area of CNV before treatment was (0.23±0.05)mm2, and that of CNV after treatment was (0.11±0.09)mm2, which was statistically significant (P < 0.05). The amplitude density of P1 wave in ring 1 before treatment was（60.90±11.62）nv/deg2,and the amplitude density of P1 wave after treatment was（89.43±11.13）nv/deg2, compared with before treatment, the difference was statistically significant (P < 0.05). No serious ocular complications such as endophthalmitis, cataract, glaucoma, retinal detachment, cardiovascular and cerebrovascular accidents occurred in 30 eyes. Conclusion Intravitreal injection of conbercept can improve the morphology and function of macular area in patients with ICNV.
关键词	康柏西普；特发性脉络膜新生血管
KeyWord	Conbercept; Idiopathic choroidal neovascularization
基金项目
页码	36-39

参考文献
相关文献

[1] Lai Timothy Y Y,Staurenghi Giovanni,Lanzetta Paolo et al. EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARI-ZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.
[J] .Retina, 2018, 38: 1464-1477.
[2] Chu Yongchao, Chen Ning, Yu Huajun et al. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
[J] .Int J Nanomedicine, 2017, 12: 1353-1368.
[3] COHEN S Y, LAROCHE A, LEGUEN Y, SOUBRANE G,COSCAS G J. Etiology of choroidal neovascularization in young patients
[J].Ophthalmology,1996,103(8):1241-1244.
[4] Ho AC,YANNUZZI LA,PISICANO K,DEROSA J.The naturaI history of idiopathic subfoveal choroidal neovascularization
[J].Ophthalmology,1995,102(5):782—789.
[5] KUMAR A, PRAKASH G, SINGH R P. Transpupillary thermothera-Py for idiopathic subfoveal choroidal neovascularization
[J]. Acta Ophthalmol Scand,2004,82(2): 205-208.
[6] Liu Bing, Bao Li, Zhang Junjun, Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up.
[J] .Medicine (Baltimore), 2016, 95: e3264.
[7] YANG F, DOU H L, MA Z, LI Y L, LU X R, HE P P, et al. Serum inflammatory factors in patients with idiopathic choroidal neovas-cularization
[J]. Ocul Immunol Inflamm, 2010, 18(5):390-394.
[8] YANG F, DOU H L, MA Z, LI Y L, LU X R, HE P P, et al. Serum inflammatory factors in patients with idiopathic choroidal neovas-cularization
[J].Ocul Immunol Inflamm, 2010, 18(5): 390-394.
[9] KANEKO Y, KITAZATO K, BASAKI Y. Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor
[J].J Cell Sci,2004,117(3):407-415.
[10] Wu Z G, ZHOU P, LI X X, WANG H, LUO D L, QIAO H Y, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling
[J]. PLoS One.2013;8(3):e57642.
[11] Dansingani Kunal K, Freund K Bailey, Optical Coherence Tomography Angiography Reveals Mature, Tangled Vascular Networks in Eyes With Neovascular Age-Related Macular Degeneration Showing Resistance to Geographic Atrophy.
[J] .Ophthalmic Surg Lasers Imaging Retina, 2015, 46: 907-12.
[12] 郑元建, 韩慧, 朱月莹. 玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管的临床疗效对比
[J].眼科新进展, 2020, 40(2):177-179.http://192.168.253.64:8088/D/Periodical_ykxjz202002018.aspx
[13] Fung Anne E, Lalwani Geeta A, Rosenfeld Philip J et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
[J] .Am J Ophthalmol, 2007, 143: 566-83.

引用本文

李天贺,翟改霞,宋文琦,王少鹏*. 玻璃体腔注射康柏西普对特发性脉络膜新生血管患者黄斑区形态和功能的影响 [J]. 国际临床研究杂志. 2025; 9; (3). 36 - 39.

文献评论

相关学者

相关机构